DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effects of psychotropic drugs on the thrombin-induced liberation of arachidonate in human platelets.

Author(s): Oruch R, Pryme IF, Holmsen H

Affiliation(s): Department of Biomedicine, University of Bergen, Jonas Lies vei 91, N-5009 Bergen, Norway. ramadhan.oruch@biomed.uib.no

Publication date & source: 2008-10, Saudi Med J., 29(10):1397-407.

Publication type: Evaluation Studies; Research Support, Non-U.S. Gov't

OBJECTIVE: To compare the effects of chlorpromazine (CPZ), prochlorperazine (PCP), trifluoperazine (TFP), clozapine (CLO), haloperidol (HPD), quetiapine (QTP), pimozide (PMZ), and olanzapine (OLP) as well as the tricyclic antidepressants amitriptyline AMI, imipramine IMI, and nortriptyline NTP on thrombin-induced liberation of arachidonic acid AA in platelets. METHODS: This work was carried out at the Department of Biomedicine, University of Bergen, Norway in 2006-2007. Human platelets pre labelled with [3H] arachidonate were incubated with thrombin in the absence and presence of the drugs, and the amount of free [3H] arachidonate liberated was determined. Myosin light chain (MLC) phosphorylation was determined in [32P] phosphate-labelled platelets after sodium dodecyl sulfate polyacrylamide gel electrophoresis. The effects of the drugs on the molecular area and surface pressure of phospholipid monolayers were determined in the Langmuir apparatus. RESULTS: All drugs reduced arachidonate liberation with the ranking order of increasing potency: OLP<QTP<HPD<AMI<IMI<PMZ<NTP<CPZ<TFP<PCP. Since phenothiazines are calmodulin antagonists, this property of the drugs was tested as reduction of thrombin-induced phosphorylation of MLC in [32P] Pi-labelled platelets. Only PCP, CPZ, TFP, and NTP reduced MLC phosphorylation. All 11 drugs studied markedly increased the mean molecular area of dipalmitoyl phosphatidylserine monolayers at 37 degrees. CONCLUSION: The mechanisms for reduction of arachidonate liberation is thought to interfere with activation of cytosolic phospholipase A2 (cPLA2) by alteration of the PLA2 phospholipid substrate structure in platelet membranes.

Page last updated: 2009-02-08

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017